Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Interest & Investment Income: 2021-2025

Historic Interest & Investment Income for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $6.6 million.

  • Krystal Biotech's Interest & Investment Income fell 9.65% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.8 million, marking a year-over-year decrease of 3.82%. This contributed to the annual value of $29.7 million for FY2024, which is 31.10% up from last year.
  • Per Krystal Biotech's latest filing, its Interest & Investment Income stood at $6.6 million for Q3 2025, which was down 11.72% from $7.5 million recorded in Q2 2025.
  • Over the past 5 years, Krystal Biotech's Interest & Investment Income peaked at $7.6 million during Q1 2024, and registered a low of $30,000 during Q2 2021.
  • Moreover, its 3-year median value for Interest & Investment Income was $7.3 million (2024), whereas its average is $6.7 million.
  • In the last 5 years, Krystal Biotech's Interest & Investment Income soared by 3,784.29% in 2022 and then dropped by 9.65% in 2025.
  • Over the past 5 years, Krystal Biotech's Interest & Investment Income (Quarterly) stood at $70,000 in 2021, then surged by 3,784.29% to $2.7 million in 2022, then surged by 176.54% to $7.5 million in 2023, then fell by 3.07% to $7.3 million in 2024, then dropped by 9.65% to $6.6 million in 2025.
  • Its last three reported values are $6.6 million in Q3 2025, $7.5 million for Q2 2025, and $7.4 million during Q1 2025.